Floatz logo

Nivolumab

Stage IVA Colon Cancer AJCC v8

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Stage IVA Colon Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Eloxatin
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2BB
FLUOROURACILUM
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2BB
Tranexamic Acid
Assaf-Harofeh Medical Center
Phase 4BB
Cetuximab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2B
Irinotecan
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2B

View all 34 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →